Bio-Rad Expands Range of Quality Controls for Abbott Clinical Diagnostics Platforms
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced an expanded portfolio of independent quality controls (QC) products, now including InteliQ and Liquichek compact vials, for the Abbott Alinity ci-series integrated clinical chemistry and immunoassay testing instruments.
“We are pleased to expand our offering of independent quality controls for the Abbott Alinity ci-series platforms,” said Dara Wright, EVP, and President of Bio-Rad’s Clinical Diagnostics Group. “Bio-Rad’s barcoded tubes and vials, combined with robust data management software, offer a flexible QC solution for a complete customer choice on Abbott Alinity ci platforms to streamline their QC workflow and enhance user experience.”
Bio-Rad is a global leader in quality control products, offering an extensive range of quality controls covering analytes for immunoassay, chemistry, cardiac assessment, immunology, diabetes, coagulation, hematology, blood gas, drugs-of-abuse, and infectious disease testing. The company’s QC data management solutions connect large peer groups of test systems and assay methods to the company’s Unity Interlaboratory Program, enabling labs to compare their results in real time with over 29,000 other labs worldwide.
To learn more about Bio-Rad’s complete QC workflow solutions, please visit: https://www.qcnet.com/Abbott
BIO-RAD, InteliQ, and Liquichek are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.